Dr. Sebastian Martinek focuses his practice on the development and management of global patent portfolios involving pharmaceutical and biotechnology innovations and medical devices. He guides clients from the early stages of patent portfolio development, through the product development process, to the development of late-stage life cycle management strategies and regulatory extension opportunities.
Sebastian regularly analyzes third-party patent portfolios and advises clients with such transactions. He provided patent advice to Celgene Corporation in its acquisition of Receptos for $7.2 billion and its global license agreement with Nogra Pharma Limited with an upfront payment of $710 million.
Other representative clients include Akebia Therapeutics, Chromocell Corporation, Hookipa Biotech AG, Follica, the Icahn School of Medicine at Mount Sinai, REGENXBIO, and Versant Venture Management.
Sebastian holds a Ph.D. in genetics and has experience in numerous technologies such as microbiome-related technologies, vaccines, small molecules, antibodies, protein- and peptide-based therapeutics, protein glycosylation, antisense-based therapeutics, RNAi, and gene therapies.
EDUCATION:
- Fordham University (J.D. 2006);
- The Rockefeller University (Ph.D. in Genetics 2001; Beckman Fellowship);
- Max Planck Institute for Biophysical Chemistry, Germany (M.A. thesis 1995);
- University of Göttingen, Germany (M.A. studies in Biochemistry, Microbiology, and Organic Chemistry 1994)
BAR ADMISSIONS :
- Massachusetts, New York, and registered to practice before the U.S. Patent and Trademark Office
EXPERIENCE :
- MedImmune builds patent portfolio for genetically engineered negative strand RNA viruses
- Warren Pharmaceuticals establishes patent portfolio for cytoprotective cytokines, including erythropoietin
- Genentech builds global patent portfolio for therapeutic antibodies
- Dainippon Sumitomo Pharma acquires oncology-focused biotechnology company Boston Biomedical for $200 million plus up to $2.2 billion in earnouts
- Myriad Genetics prevails in closely watched Federal Circuit appeal concerning fundamental questions of patent eligibility for isolated DNA molecules
- Martek Biosciences wins across-the-board victory in biotech dispute before five-judge Federal Circuit panel.
Cost
Rate : $$$
